Treatments are delivered via a handheld device, which transmits the ultrasound waves through the skins surface
Established therapies such as platelet-rich plasma (PRP) have more extensive clinical evidence and regulatory approval for certain applications
This activation occurs through a mechanism distinct from SSRIs, potentially explaining why TREK-1 channel blockers may help people who do not respond to conventional serotonin-based treatments
Qsymia (phentermine-topiramate) is not licensed for use in the UK by the MHRA Wegovy (semaglutide) is a GLP-1 receptor agonist licensed in the UK and should not be combined with other weight management products according to its Summary of Product Characteristics No clinical trials have investigated the safety or efficacy of combining these two medications Potential risks include cardiovascular effects, amplified gastrointestinal side effects, and central nervous system disturbances UK guidance from NICE recommends single-agent pharmacotherapy optimised within specialist weight management services Sequential therapy or bariatric surgery referral are evidence-based alternatives for patients not responding to single-agent treatment Table of Contents Understanding Qsymia and Wegovy: Different Mechanisms for Weight Loss Can You Take Qsymia and Wegovy Together
A large, rigorous, clearly negative trial is not a wasted trial
Can semaglutide improve overall metabolic health
